Perrigo signs $8.6bn Elan takeover deal
This article was originally published in Scrip
Perrigo has agreed a cash and shares takeover of Elan which values the Irish firm at $16.50 per share. The total value of the deal is $8.6bn at Perrigo's share price of $134.23 at close of business on 26 July.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.